TFA
BIB icon

Toth Financial Advisory’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Toth Financial Advisory’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
1,022
+25
+3% +$2.1K 0.01% 294
2026
Q1 		$81.3K Hold
997
– – 0.01% 297
2025
Q4 		$79.5K Hold
997
– – 0.01% 290
2025
Q3 		$59.4K Hold
997
– – 0.01% 323
2025
Q2 		$45.7K Sell
997
-4,629
-82% -$204K 0.01% 322
2025
Q1 		$271K Sell
5,626
-3,030
-35% -$162K 0.03% 195
2024
Q4 		$439K Sell
8,656
-2,799
-24% -$166K 0.05% 165
2024
Q3 		$730K Sell
11,455
-1,201
-9% -$77.5K 0.09% 144
2024
Q2 		$750K Sell
12,656
-13,455
-52% -$744K 0.1% 136
2024
Q1 		$1.5M Buy
26,111
+14,870
+132% +$862K 0.19% 106
2023
Q4 		$641K Buy
11,241
+1,655
+17% +$77.6K 0.09% 149
2023
Q3 		$460K Sell
9,586
-320
-3% -$16.4K 0.07% 153
2023
Q2 		$515K Buy
9,906
+815
+9% +$44.9K 0.07% 144
2023
Q1 		$493K Sell
9,091
-7,880
-46% -$445K 0.08% 150
2022
Q4 		$979K Buy
16,971
+9,440
+125% +$532K 0.16% 108
2022
Q3 		$359K Sell
7,531
-566
-7% -$30.2K 0.07% 149
2022
Q2 		$392K Sell
8,097
-1,550
-16% -$78.9K 0.07% 148
2022
Q1 		$598K Sell
9,647
-340
-3% -$20.9K 0.09% 150
2021
Q4 		$810K Sell
9,987
-11,223
-53% -$962K 0.11% 141
2021
Q3 		$2.01M Buy
21,210
+5,773
+37% +$584K 0.31% 88
2021
Q2 		$1.52M Buy
15,437
+5,215
+51% +$455K 0.23% 98
2021
Q1 		$855K Sell
10,222
-11,310
-53% -$1.07M 0.14% 117
2020
Q4 		$1.86M Sell
21,532
-25
-0.1% -$1.94K 0.32% 79
2020
Q3 		$1.51M Sell
21,557
-3,255
-13% -$231K 0.29% 83
2020
Q2 		$1.8M Buy
24,812
+6,395
+35% +$408K 0.39% 72
2020
Q1 		$852K Buy
18,417
+11,275
+158% +$628K 0.25% 84
2019
Q4 		$441K Buy
7,142
+512
+8% +$27.3K 0.09% 139
2019
Q3 		$282K Sell
6,630
-166
-2% -$7.87K 0.06% 146
2019
Q2 		$352K Sell
6,796
-2,705
-28% -$135K 0.08% 126
2019
Q1 		$527K Buy
9,501
+575
+6% +$31K 0.12% 106
2018
Q4 		$376K Sell
8,926
-19,107
-68% -$997K 0.1% 109
2018
Q3 		$1.95M Buy
28,033
+70
+0.3% +$4.58K 0.43% 69
2018
Q2 		$1.6M Sell
27,963
-310
-1% -$16.9K 0.37% 75
2018
Q1 		$1.56M Buy
28,273
+452
+2% +$27.1K 0.38% 74
2017
Q4 		$1.56M Buy
27,821
+10
+0% +$564 0.37% 76
2017
Q3 		$1.7M Buy
27,811
+5,821
+26% +$331K 0.43% 71
2017
Q2 		$1.17M Buy
21,990
+22
+0.1% +$1.07K 0.31% 80
2017
Q1 		$1.06M Buy
+21,968
New +$1.02M 0.28% 84
2016
Q4 		– Sell
-16,310
Closed -$790K – 119
2016
Q3 		$790K Buy
+16,310
New +$775K 0.23% 91

Other funds holding BIB

KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
AIM
Axiom Investment Management New York $150M AUM

Toth Financial Advisory's BIB Position: Q2 2026 in Review

Toth Financial Advisory increased its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 2.5% in Q2 2026, buying an estimated $2.1K and bringing the position to 1,022 shares worth $103K. The position accounts for 0.01% of the portfolio, ranked #294.

Toth Financial Advisory first reported a position in BIB in Q3 2016 and has held it in 39 quarters since. The position peaked at $2.01M in Q3 2021. 5 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Toth Financial Advisory held 1,022 shares of ProShares Ultra NASDAQ Biotechnology worth $103K as of Q2 2026.
  • Toth Financial Advisory bought 25 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $2.1K.
  • ProShares Ultra NASDAQ Biotechnology made up 0.01% of Toth Financial Advisory's portfolio in Q2 2026, its #294 holding.
  • Toth Financial Advisory first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and has held it in 39 quarters since.
  • Toth Financial Advisory's ProShares Ultra NASDAQ Biotechnology position peaked at $2.01M in Q3 2021.
  • 5 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.